(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.36%) $78.76
(0.32%) $2.20
(0.10%) $2 333.60
(0.29%) $27.70
(0.26%) $967.40
(-0.05%) $0.928
(-0.45%) $10.83
(-0.12%) $0.796
(-0.11%) $91.35
0.23% ¥ 1 714.00
Live Chart Being Loaded With Signals
Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally...
Stats | |
---|---|
Tagesvolumen | 15 400.00 |
Durchschnittsvolumen | 0.00 |
Marktkapitalisierung | 0.00 |
Last Dividend | ¥20.00 ( 2022-09-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 0.0000163 |
ATR14 | ¥0 (0.00%) |
Nissui Pharmaceutical Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Nissui Pharmaceutical Finanzdaten
Annual | 2022 |
Umsatz: | ¥16.66B |
Bruttogewinn: | ¥5.26B (31.57 %) |
EPS: | ¥127 333 333 |
FY | 2022 |
Umsatz: | ¥16.66B |
Bruttogewinn: | ¥5.26B (31.57 %) |
EPS: | ¥127 333 333 |
FY | 2021 |
Umsatz: | ¥12.38B |
Bruttogewinn: | ¥4.20B (33.90 %) |
EPS: | ¥71 190 746 |
FY | 2020 |
Umsatz: | ¥12.77B |
Bruttogewinn: | ¥5.73B (44.83 %) |
EPS: | ¥44 054 372 |
Financial Reports:
No articles found.
Nissui Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥20.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.000 | 2001-03-27 |
Last Dividend | ¥20.00 | 2022-09-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 38 | -- |
Total Paid Out | ¥454.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.24 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 1.462 | |
Div. Directional Score | 6.19 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8281.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7649.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
6850.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
6200.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4927.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4097.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3302.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2378.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
9308.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8038.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0688 | 1.500 | 8.62 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0310 | 1.200 | 8.97 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0352 | 1.500 | -0.720 | -1.080 | [0.1 - 1] |
payoutRatioTTM | 0.875 | -1.000 | 1.248 | -1.248 | [0 - 1] |
currentRatioTTM | 8.29 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.255 | 0.800 | 7.32 | 5.86 | [0.8 - 2.5] |
cashRatioTTM | 1.248 | 1.500 | 4.18 | 6.27 | [0.2 - 2] |
debtRatioTTM | 0.00306 | -1.500 | 9.95 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 24.23 | 1.000 | 2.14 | 2.14 | [3 - 30] |
operatingCashFlowPerShareTTM | 111 778 000 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 100 889 000 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00347 | -1.500 | 9.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.316 | 1.000 | 8.07 | 8.07 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.103 | 1.000 | 9.93 | 9.93 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.90 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.451 | 0.800 | -0.326 | -0.261 | [0.5 - 2] |
Total Score | 10.92 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.0000135 | 1.000 | -0.101 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0352 | 2.50 | -0.463 | -1.080 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 100 889 000 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 111 778 000 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.875 | 1.500 | 1.248 | -1.248 | [0 - 1] |
pegRatioTTM | -0.0000003 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0604 | 1.000 | -0.990 | 0 | [0.1 - 0.5] |
Total Score | 1.462 |
Nissui Pharmaceutical
Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally. It offers in vitro diagnostics and medical devices; culture media for microbiological testing; products for antimicrobial susceptibility tests, microorganism identification, and immunological tests; and quality control serum, which is used for ensuring the accuracy of clinical diagnoses. In addition,, the company provides microbiological testing products for food poisoning detection; immunosorbent assays for the detection of allergies to food items, such as eggs, wheat, milk, shrimp, crabs, buckwheat, peanuts, etc.; and culture media and reagents for regenerative medicine. Further, it supplies testing agents and bulk products to diagnostic agent manufacturers; and CompactDry, a dry medium that is used for coliform counting for food manufacturers. The company was formerly known as Nissan Research Institute Co., Ltd. and changed its name to Nissui Pharmaceutical Co., Ltd. in 1962. Nissui Pharmaceutical Co., Ltd. was founded in 1935 and is headquartered in Tokyo, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.